Developer docs
API playgroundTry for free, no card

Search company profiles

Anjarium Biosciences

Full company profile

uuid000276i

Namestring
Anjarium Biosciences
Websiteurl
anjarium.com
Company typeenum
Private
Founded yearint
2017
Short descriptiontext

Anjarium Biosciences is a Zurich-based private biotech founded in 2017 developing a proprietary exosome-based delivery platform for non-viral gene therapies, with therapeutic programs advancing toward clinical development for genetic diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
exosome therapeutics, non-viral gene therapy, drug delivery platform, biopharmaceutical research, therapeutic development
Industry2 codes
1RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
CodeHLAAADAGPrimaryYes
2Neurology/CNS Gene Therapies
CodeHLAAACAHPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Gene Therapy / Exosome Therapeutics
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Anjarium Biosciences develops exosome-based therapeutics as a novel class of non-viral gene therapies to address genetic diseases. The company operates a proprietary exosome platform that enables the development of therapeutic programs targeting unmet medical needs, currently advancing pipeline candidates toward clinical development.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Exosome-based therapeutics platform
CategoryExosome-based gene therapy platform
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
1Codiak BioSciences
TypeDirect peer
Description

Codiak BioSciences developed engineered exosome-based therapeutics (engEx platform) for various diseases, including oncology and rare diseases. It is the most direct peer to Anjarium as a platform company leveraging exosomes for therapeutic delivery.

2Evox Therapeutics
TypeDirect peer
Description

Evox Therapeutics is a UK-based biotech developing exosome-based therapeutics for rare diseases and CNS indications. It is a direct competitor in the engineered exosome delivery platform space, with similar therapeutic focus areas.

3Capricor Therapeutics
TypeDirect peer
Description

Capricor Therapeutics develops cell-derived exosome and extracellular vesicle-based therapeutics, including for Duchenne muscular dystrophy and COVID-19 indications. The company shares the exosome therapeutic modality focus with Anjarium.

4Generation Bio
TypeDirect peer
Description

Generation Bio is a non-viral gene therapy company developing lipid nanoparticle-based delivery for genetic diseases. It is a direct peer in the non-viral gene therapy space, sharing Anjarium's positioning away from viral vectors.

5ILIAS Biologics
TypeEmerging player
Description

ILIAS Biologics is a Korea-based biotech developing exosome-based therapeutics, including anti-inflammatory and protein delivery applications. It represents an emerging player in the same engineered exosome therapeutic space.

6Aegle Therapeutics
TypeEmerging player
Description

Aegle Therapeutics is a US-based biotech developing extracellular vesicle-based therapies for regenerative medicine and rare diseases. It is comparable as an emerging exosome therapeutic company targeting similar applications.

7Verve Therapeutics
TypeEmerging player
Description

Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease using non-viral delivery approaches. It is an emerging player in the non-viral gene therapy space with comparable delivery technology focus.

8uniQure
TypeBroad incumbent
Description

uniQure is a leading gene therapy company with an approved AAV-based product (Hemgenix). As a broad incumbent in gene therapy, it represents the established viral vector approach that non-viral platforms like Anjarium's must compete against.

9BioMarin Pharmaceutical
TypeBroad incumbent
Description

BioMarin is a major rare disease biotech with a gene therapy pipeline (e.g., Roctavian for hemophilia A). It is a broad incumbent in the gene therapy space and a potential acquirer or partner for emerging platforms.

10Lonza Group
TypeOthers
Description

Lonza is a leading CDMO serving the cell and gene therapy industry. It is adjacent to Anjarium as a potential manufacturing partner and ecosystem participant in the exosome/gene therapy development space.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Anjarium Biosciences

Gene Therapy / Exosome Therapeuticsanjarium.com

Anjarium Biosciences is a Zurich-based private biotech founded in 2017 developing a proprietary exosome-based delivery platform for non-viral gene therapies, with therapeutic programs advancing toward clinical development for genetic diseases.

Anjarium Biosciences firmographics

Firmographics
Name
Anjarium Biosciences
Website
https://anjarium.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Anjarium Biosciences is a Zurich-based private biotech founded in 2017 developing a proprietary exosome-based delivery platform for non-viral gene therapies, with therapeutic programs advancing toward clinical development for genetic diseases.
Ownership category
akta.pro rank

Anjarium Biosciences industry classification

Industry
Product category
Gene Therapy / Exosome Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)
akta.pro secondary industry
Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

  • Exosome therapeutics
  • Non-viral gene therapy
  • Drug delivery platform
  • Biopharmaceutical research
  • Therapeutic development

Where Anjarium Biosciences is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Anjarium Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Anjarium Biosciences product offering

Product offering

Core offering

Anjarium Biosciences develops exosome-based therapeutics as a novel class of non-viral gene therapies to address genetic diseases. The company operates a proprietary exosome platform that enables the development of therapeutic programs targeting unmet medical needs, currently advancing pipeline candidates toward clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Exosome-based therapeutics platform

Companies that use Anjarium Biosciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Anjarium Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Anjarium Biosciences partnerships and signals

Strategic signal

Scale indicators3 records

Anjarium Biosciences competitors and assessment

Company assessment

Direct peers

  • Codiak BioSciences: Codiak BioSciences developed engineered exosome-based therapeutics (engEx platform) for various diseases, including oncology and rare diseases. It is the most direct peer to Anjarium as a platform company leveraging exosomes for therapeutic delivery.
  • Evox Therapeutics: Evox Therapeutics is a UK-based biotech developing exosome-based therapeutics for rare diseases and CNS indications. It is a direct competitor in the engineered exosome delivery platform space, with similar therapeutic focus areas.
  • Capricor Therapeutics: Capricor Therapeutics develops cell-derived exosome and extracellular vesicle-based therapeutics, including for Duchenne muscular dystrophy and COVID-19 indications. The company shares the exosome therapeutic modality focus with Anjarium.
  • Generation Bio: Generation Bio is a non-viral gene therapy company developing lipid nanoparticle-based delivery for genetic diseases. It is a direct peer in the non-viral gene therapy space, sharing Anjarium's positioning away from viral vectors.

Emerging players

  • ILIAS Biologics: ILIAS Biologics is a Korea-based biotech developing exosome-based therapeutics, including anti-inflammatory and protein delivery applications. It represents an emerging player in the same engineered exosome therapeutic space.
  • Aegle Therapeutics: Aegle Therapeutics is a US-based biotech developing extracellular vesicle-based therapies for regenerative medicine and rare diseases. It is comparable as an emerging exosome therapeutic company targeting similar applications.
  • Verve Therapeutics: Verve Therapeutics develops in vivo gene editing therapies for cardiovascular disease using non-viral delivery approaches. It is an emerging player in the non-viral gene therapy space with comparable delivery technology focus.

Broad incumbents

  • uniQure: uniQure is a leading gene therapy company with an approved AAV-based product (Hemgenix). As a broad incumbent in gene therapy, it represents the established viral vector approach that non-viral platforms like Anjarium's must compete against.
  • BioMarin Pharmaceutical: BioMarin is a major rare disease biotech with a gene therapy pipeline (e.g., Roctavian for hemophilia A). It is a broad incumbent in the gene therapy space and a potential acquirer or partner for emerging platforms.

Others

  • Lonza Group: Lonza is a leading CDMO serving the cell and gene therapy industry. It is adjacent to Anjarium as a potential manufacturing partner and ecosystem participant in the exosome/gene therapy development space.

Market position

Customer concentration

Anjarium Biosciences social profiles

Digital presence

Anjarium Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Anjarium Biosciences leadership team

Management profile

Number of profiles

Profiles5 records

Anjarium Biosciences funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Anjarium Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anjarium Biosciences

What does Anjarium Biosciences do?

Anjarium Biosciences develops exosome-based therapeutics as a novel class of non-viral gene therapies to address genetic diseases. The company operates a proprietary exosome platform that enables the development of therapeutic programs targeting unmet medical needs, currently advancing pipeline candidates toward clinical development.

Is Anjarium Biosciences a public or private company?

Anjarium Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Anjarium Biosciences founded?

Anjarium Biosciences was founded in 2017. It employs 11 to 50 people.

Where is Anjarium Biosciences based?

Anjarium Biosciences is headquartered in Schlieren, Switzerland, in the Europe region.

Who are Anjarium Biosciences's main competitors?

Direct peers on record are Codiak BioSciences, Evox Therapeutics, Capricor Therapeutics and Generation Bio. Emerging players are ILIAS Biologics, Aegle Therapeutics and Verve Therapeutics. Broad incumbents are uniQure and BioMarin Pharmaceutical. Lonza Group is listed as an others.

Does Anjarium Biosciences have an API?

No public API is recorded for Anjarium Biosciences.

What industry is Anjarium Biosciences in?

Anjarium Biosciences's product category is Gene Therapy / Exosome Therapeutics. Its primary akta.pro industry code is HLAAADAG, RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics), with a secondary code of HLAAACAH, Neurology/CNS Gene Therapies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioinformantAdvances in Exosome Isolation and Characterization: Technologies, Commercial Vendors, and Clinical ImplicationsThe article reviews various technologies and commercial vendors involved in the isolation and characterization of exosomes for therapeutic applications. It highlights that while ultracentrifugation is common, researchers increasingly use commercial kits from companies like Lonza, Thermo Fisher Scientific, and System Biosciences to facilitate research and clinical trials. The text also notes the growing market for exosome characterization services provided by firms such as Anjarium Biosciences and ZenBio.PR NewswireANJARIUM BIOSCIENCES PRESENTS DATA DEMONSTRATING NOVEL SYNTHETIC DNA APPLICATIONS FOR CELL AND GENE THERAPIES at 27th ANNUAL ASGCT MEETINGAnjarium Biosciences presented five scientific posters at the 27th Annual ASGCT Meeting in Baltimore, demonstrating the advantages of its synthetic DNA platform for cell and gene therapy applications. The data highlighted significant improvements in purity, scalability, and speed compared to conventional plasmids for mRNA, AAV, and lentiviral vector production. This presentation supports the company's strategic pivot toward becoming a tools and technology provider for genetic medicine manufacturers.PR NewswireAnjarium Biosciences appoints ex-Novartis gene therapy leader Otmane Boussif, DSc as Chief Technology OfficerAnjarium Biosciences AG, a Swiss biotech company developing non-viral gene therapies, announced the appointment of Otmane Boussif, DSc as its new Chief Technology Officer. Boussif brings more than 25 years of experience in biopharmaceutical technology development and bioprocessing, most recently serving as CTO at Sensorion and previously holding senior roles at Novartis including Global Head of Cell & Gene Therapy Technical Development. The appointment is expected to support Anjarium's advancement of its pxDNA and Hybridosome™ platforms targeting diseases with high unmet needs.PR NewswireAnjarium Biosciences Appoints Gaurav Shah as Chairperson and Douglas Fambrough as Non-executive DirectorAnjarium Biosciences AG announced the expansion of its Board of Directors with the appointments of Gaurav Shah as independent Non-executive Director and Chairperson, and Douglas Fambrough as independent Non-executive Director. Both appointees bring extensive gene therapy and corporate development expertise, with Shah currently serving as founding CEO of Rocket Pharma and Fambrough having co-founded Dicerna, which was acquired by Novo Nordisk for $3.3 billion in 2021. The company stated these appointments will strengthen its board as it advances its non-viral gene therapy platform and pipeline.FinSMEsAnjarium Biosciences Raises $61M in Series A FinancingAnjarium Biosciences closed a CHF55.5M ($61M) Series A financing round co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures, and Surveyor Capital. The company intends to use the funds to expand its team, advance its platform, and progress several therapeutic pipeline programs towards clinical development. Three investors will join the company’s Board of Directors as part of the transaction.PR NewswireAnjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene TherapiesAnjarium Biosciences closed a CHF 55.5 million ($61 million) Series A financing round co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures, and Surveyor Capital. The funding will support the expansion of its team and the advancement of its non-viral gene therapy platform toward clinical development.startupticker.chAnjarium Biosciences Raises CHF 55.5 Million Series A FinancingSwiss-based Anjarium Biosciences announced a Series A financing of CHF 55.5 million, co-led by Abingworth and Gimv with participation from Omega Funds, Pfizer Ventures and Surveyor Capital. The Schlieren company, founded in 2016, will use the funds to expand its team, platform and pipeline programs toward clinical development. Three investors will join the Board of Directors.